Search

Author/Creator DiNardo, C. D.

1. P581: PHASE II STUDY OF LOWER-INTENSITY FRONTLINE THERAPY FOR NEWLY DIAGNOSED PATIENTS WITH AML WHO ARE UNFIT OR OTHERWISE NOT ELIGIBLE FOR FRONTLINE CLINICAL TRIALS. (23rd June 2022)

Authors:
Venugopal, S.; Jabbour, E.; Pemmaraju, N.; Montalban-Bravo, G.; Chien, K. S.; Daver, N.; Jain, N.; Burger, J.; Alvarado, Y.; Maiti, A.; DiNardo, C. D.; Borthakur, G.; Malla, R.; Garcia-Manero, G.; Ravandi, F.; Kantarjian, H.; Kadia, T.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
480
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. P765: UPDATED ENROLLMENT AND RESULTS FROM THE PHASE 1 SUBSTUDY OF IVOSIDENIB IN PATIENTS WITH IDH1-MUTANT RELAPSED/REFRACTORY MYELODYSPLASTIC SYNDROME (R/R MDS). (23rd June 2022)

Authors:
DiNardo, C. D.; Foran, J. M.; Watts, J. M.; Stein, E. M.; de Botton, S.; Fathi, A. T.; Prince, G. T.; Stone, R. M.; Patel, P. A.; Roboz, G. J.; Arellano, M. L.; Erba, H. P.; Pigneux, A.; Baratam, P.; Stuart, R. K.; Thomas, X.; Lemieux, I. R.; Bai, X.; Kapsalis, S. M.; Garcia-Manero, G.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
660
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search